Drug trial results and the stock moves that follow

13 resultsPhase 3
Missed endpoint

Firmonertinib

Phase 3 n=398 Metastatic Non-Small Cell Lung Cancer

ArriVent AVBP

24h stock move −48.74%
Met endpoint

VAX-31

Phase 3 n=4,049 Pneumococcal Disease

Vaxcyte PCVX

24h stock move +29.23%
Met endpoint

tabirafusp

Phase 3 n=675 Wet Age-related Macular Degeneration

Kodiak Sciences KOD

24h stock move +168.93%
Met endpoint

Barzolvolimab

Phase 3 n=963 Chronic Spontaneous Urticaria

Celldex CLDX

24h stock move −11.59%
Met endpoint

DT120

Phase 3 Generalized Anxiety Disorder

Definium Therapeutics DFTX

24h stock move +4.78%
Met endpoint

Avexitide

Phase 3 n=75 Post Bariatric Hypoglycemia

Amylyx Pharmaceuticals AMLX

24h stock move +66.59%
Met endpoint

DT120

Phase 3 Generalized Anxiety Disorder

Definium Therapeutics DFTX

24h stock move +6.09%
Missed endpoint

TNX-103

Phase 3 n=230 Pulmonary Hypertension

Tenax Therapeutics TENX

24h stock move −89.29%
Met endpoint

ZYNLONTA

Phase 3 n=440 Relapsed Diffuse Large B-Cell Lymphoma

ADC Therapeutics ADCT

24h stock move −55.84%
Met endpoint

ublituximab

Phase 3 Relapsing Forms of Multiple Sclerosis

TG Therapeutics TGTX

24h stock move −0.97%
Met endpoint

RGX-202

Phase 3 Duchenne Muscular Dystrophy

REGENXBIO RGNX

24h stock move −38.15%
Met endpoint

LUMRYZ

Phase 3 Idiopathic Hypersomnia

Alkermes plc. ALKS

24h stock move +7.13%
Met endpoint

ARIKAYCE

Phase 3 n=425 Mycobacterium Infections, Nontuberculous

Insmed INSM

24h stock move +8.25%

Daily roundups

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.